Exelixis IGF-1R/Src inhibitor XL228 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis’ IGF-1R/Src inhibitor  XL228 to show signs of Clinical Benefit inpatients with advanced malignancies

Antisense Therapeutics IGF-1R agent ATL-1101 effective in vivo

Antisense Therapeutic’s IGF-1R antisense product ATL1101 has been found to suppress tumor growth in mouse models of prostate cancer

Roche to initiate Phase II trial of IGF-1R MAb R1507 in NSCLC

Roche and Genmab are preparing to initatea phase II trial of IGF-1R MAb R1507 in NSCLC in combination with tarceva

ImClone initiate randomized Phase II trial of IMC-A12 in breast cancer

ImClone Systems have initiated a phase II clinical trial of its anti-IGF-1R MAb IMC-A12 in women with advanced breast cancer

Pfizers IGF-1R MAb CP-751,871 effective in NSCLC

Phase II data presented at the European of Medical Oncology (ESMO) show that Pfizer’s IGF-1R inhibitor CP-751,871 shows efficacy in patients with non-small cell lung cancer (NSCLC).

Coadministration of IGF-1R inhibitor BMS-554417 with HER2 inhibitor BMS-599626 increases antiproliferative activity

Co administration of IGF-1R inhibitor, BMS-554417 with HER2 inhibitor BMS-599626 resulted in a synergistic antiproliferative effect in ovarian cancer cell lines.

ImClone initate Phase II trial in prostate cancer comparing IMC-A12 and IMC-1121B

ImClone have commenced enrollment in a Phase II trial with either IMC-A12 or IMC-1121B in patients with advanced prostate cancer. IMC-A12 is a fully human, IgG1 anti-IGF-1 receptor (IGF-1R) monoclonal antibody and IMC-1121B is its fully human, IgG1 anti-vascular growth factor receptor-2 (VEGFR-2) monoclonal antibody.

IGF-1R/FAK inhibitor TAE226 shows efficacy in preclinical studies

Novartis’ FAK/IGF-1R inhibitor TAE226 has shown anti tumor activity in Barrett’s esophageal adenocarcinoma tissues

ImClone initiate Phase II study of IGF-1R MAb for Advanced Soft Tissue Sarcoma

ImClone Systems have announced the start of a Phase II clinical trial of IMC-A12, its IGF-1R monoclonal antibody in adolescents and adult patients with several types of soft tissue sarcoma.

Axelar initiate Phase I/II trial with IGF-1R drug AXL1717

Axelar has initiated a Phase I/II clinical trial in cancer patients with its insulin-like growth factor-1 receptor inhibitor AXL1717